Fig. 4From: Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysisSensitivity analysis showing pooled HRs for HCC risk, including only studies with participants without liver diseaseBack to article page